Human health depends on a healthy planet. Climate change, pollution, water scarcity and biodiversity loss are affecting people’s health, straining health systems and disproportionately impacting the most underserved communities.
As we grow to serve more people, the need for materials, energy and water increases. Our responsibility to reduce our environmental impact grows with us.
Through our Circular for Zero programme, we take science-based action across our value chain, working with suppliers, partners and global alliances to reduce emissions, protect nature, rethink chemistry and drive circularity by design.
Climate change is one of the greatest threats to human health. We are working towards net zero emissions across our value chain by 2045, including a 75% reduction in emissions from our own operations and a 33% reduction across our value chain by 2033 from a 2024 baseline.
We work with suppliers and manufacturing partners to cut emissions and environmental impact across our supply chain.
Nature provides the water, land and raw materials that support both health and healthcare. We aim to mitigate impacts and dependencies on natural resources to halt the loss of nature by 2033 and contribute to global nature positive outcomes by 2045. We also set targets for deforestation-free sourcing, water restoration and regenerative agriculture.
The medicines we make should not create unnecessary harm to the environment. Our ambition is to reduce the use of toxic chemicals and minimise pharmaceutical residues from entering the environment.
By designing for circularity, we are reducing waste, using resources more efficiently and keeping materials in use for longer. Our target is to have all new products assessed by our Circular Product Design Framework and Life Cycle Assessment, covering our top 30 best-selling products by the end of 2027.
Our device take-back programme gives used injection devices a new life.
